Tetragenetics is an emerging biotechnology firm founded in 2004, specializing in providing an economical platform technology for the production of genetically engineered proteins. The company's expertise lies in producing challenging eukaryotic membrane and secretory proteins, which are typically hard to express using conventional systems. These proteins play a crucial role in the development of vaccine antigens, monoclonal antibodies, and therapeutic proteins for both human and animal health. The latest financial update for Tetragenetics includes a $1.01M debt financing investment received on 29th September 2020. This investment signifies a vote of confidence in the company's innovative approach and its potential to make a significant impact in the Biopharma and Biotechnology industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Debt Financing | $1.01M | - | 29 Sep 2020 | |
| Venture Round | $809.77K | - | 19 Jul 2018 | |
| Venture Round | Unknown | 1 |
|
02 May 2017 |
| Grant | $1.54M | 1 | National Institutes of Health | 14 Jan 2016 |
| Venture Round | $338.19K | 1 |
|
09 Mar 2015 |
No recent news or press coverage available for Tetragenetics.
We care about your data, and we'd love to use cookies make your experience better.
